Pharmaceutical care in patients with gastric cancer treated with capecitabine: A randomized clinical trial
Authors:
- Patrícia Kaiser Pedroso CavaPCPatrícia Kaiser Pedroso Cava
- Camille Nigri CursinoCCCamille Nigri Cursino
- Larissa Dos Santos Sebould MarinhoLMLarissa Dos Santos Sebould Marinho
- Ana Clara Duarte Dos SantosASAna Clara Duarte Dos Santos
- Ariela Dutra Norberto De OliveiraAOAriela Dutra Norberto De Oliveira
- Larissa Rodrigues NascimentoLNLarissa Rodrigues Nascimento
- Vanessa Cristiane Da Silva FerreiraVFVanessa Cristiane Da Silva Ferreira
- Dulce Helena Nunes CoutoDCDulce Helena Nunes Couto
- Jessica Pronestino De Lima MoreiraJMJessica Pronestino De Lima Moreira
- Thaísa Amorim NogueiraTNThaísa Amorim Nogueira
- Selma Rodrigues De CastilhoSCSelma Rodrigues De Castilho
- Sabrina Calil-EliasSCSabrina Calil-Elias
- 27 August 2026
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Abstract
Introduction: Cancer poses a major challenge to global health, impacting individuals, communities and societies worldwide. A significant proportion of global morbidity and mortality from neoplasms is accounted for by gastrointestinal tumors, due to their high incidence and lethality. Capecitabine, an oral antineoplastic agent, has brought advances in treatment, but requires caution regarding adherence and adverse events. In this context, it is believed that pharmaceutical care can significantly contribute to optimizing therapy and promoting better clinical outcomes. Objective: The aim of this study is to assess the advantages of pharmaceutical care for patients with gastric cancer who are being treated with capecitabine. Methods: A multicentre, prospective, longitudinal study was conducted with patients with gastric cancer using capecitabine. Patients were randomised into two groups, namely control (pharmaceutical guidance) and intervention (pharmaceutical care). Sociodemographic, clinical, and therapeutic data were collected, and adverse events were identified, classified and analysed, with impacts such as dose suspension or reduction, emergencies, hospitalisations and use of additional drugs being considered. Quality of life was assessed before and after treatment. Results: Thirty-one patients were selected, 16 of whom were in the intervention group. This group completed more treatment cycles, although it had a higher number of adverse events, with less severity. All patients who received pharmaceutical care were adherent to their treatment. In contrast, patients who did not receive pharmaceutical care had more suspensions and dose reductions. They also had a significant worsening of overall functional capacity. In addition, their symptoms such as nausea, vomiting, and diarrhea were aggravated. In the intervention group, however, there was an improvement in these symptoms. Conclusion: The study highlights the importance of pharmaceutical care in capecitabine treatment, especially in the management of adverse events, treatment adherence and promotion of quality of life. Despite the small sample size, the results reinforce the role of the pharmacist in the care of these patients and indicate the need for further studies with larger samples.Keywords
This publication has 27 references indexed in Scilit:
- Meta‐Analysis of Capecitabine versus 5‐Fluorouracil in Advanced Gastric CancerEvidence-Based Complementary and Alternative Medicine, 2023
- Pharmacist-Led Management Improves Treatment Adherence and Quality of Life in Opioid-Tolerant Patients With Cancer Pain: A Randomized Controlled TrialPain and Therapy, 2022
- Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping ReviewJNCI: Journal of the National Cancer Institute, 2020
- PaCIR: A tool to enhance pharmacist patient care intervention reportingJournal of the American Pharmacists Association, 2019
- Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer centerJournal of Oncology Pharmacy Practice, 2018
- Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World StudyDrugs in R&D, 2016
- Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?Annals of Oncology, 2009
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancerCancer Chemotherapy and Pharmacology, 2007
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993